CA2259194C - Compositions transdermiques contenant du levosimendane - Google Patents

Compositions transdermiques contenant du levosimendane Download PDF

Info

Publication number
CA2259194C
CA2259194C CA002259194A CA2259194A CA2259194C CA 2259194 C CA2259194 C CA 2259194C CA 002259194 A CA002259194 A CA 002259194A CA 2259194 A CA2259194 A CA 2259194A CA 2259194 C CA2259194 C CA 2259194C
Authority
CA
Canada
Prior art keywords
preparation
pharmaceutically acceptable
levosimendan
drug
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002259194A
Other languages
English (en)
Other versions
CA2259194A1 (fr
Inventor
Arto Urtti
Jouni Hirvonen
Lasse Lehtonen
Saila Antila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614098.3A external-priority patent/GB9614098D0/en
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of CA2259194A1 publication Critical patent/CA2259194A1/fr
Application granted granted Critical
Publication of CA2259194C publication Critical patent/CA2259194C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'administration transdermique de lévosimendane ou de (-)-[[4-(1,4,5,6-tétrahydro-4-méthyl-6-oxo-3-pyridazinyl)phényl]hydrazono]propanedinitrile, ou d'un sel pharmaceutiquement acceptable de cette composition. Les préparations transdermiques de lévosimendane peuvent se présenter sous la forme d'un onguent, d'une émulsion, d'une lotion, d'une solution, d'un gel, d'une crème, d'une bande adhésive ou d'un dispositif d'administration transdermique, y compris un dispositif ionophorétique.
CA002259194A 1996-07-05 1997-06-26 Compositions transdermiques contenant du levosimendane Expired - Fee Related CA2259194C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9614098.3 1996-07-05
GBGB9614098.3A GB9614098D0 (en) 1996-07-05 1996-07-05 Transdermal delivery of levosimendan
PCT/FI1997/000412 WO1998001111A1 (fr) 1996-07-05 1997-06-26 Compositions transdermiques contenant du levosimendane

Publications (2)

Publication Number Publication Date
CA2259194A1 CA2259194A1 (fr) 1998-01-15
CA2259194C true CA2259194C (fr) 2007-06-19

Family

ID=38282788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002259194A Expired - Fee Related CA2259194C (fr) 1996-07-05 1997-06-26 Compositions transdermiques contenant du levosimendane

Country Status (1)

Country Link
CA (1) CA2259194C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8430839B2 (en) 2011-04-19 2013-04-30 Palo Alto Research Center Incorporated Drug delivery devices and methods with collimated gas stream and drug reservoir
US8486002B2 (en) * 2011-04-19 2013-07-16 Palo Alto Research Center Incorporated Drug delivery devices and methods with collimated gas stream and release-activatable tape
US8388569B2 (en) 2011-04-19 2013-03-05 Xerox Corporation Delivery devices and methods with collimated gas stream and particle source

Also Published As

Publication number Publication date
CA2259194A1 (fr) 1998-01-15

Similar Documents

Publication Publication Date Title
EP0941063B1 (fr) Compositions transdermiques contenant du levosimendane
AU656755B2 (en) Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers
CA1329547C (fr) Compositions stimulant la penetration transcutanee au moyen du mono-oleate de glycerine
EP0028526B1 (fr) Formulation contenant de la nitroglycérine et éventuellement d'autres médicaments et sa préparation
CA2135925C (fr) Emploi de la glycerine pour moderer l'administration de medicaments par voie transdermale
EP1796676B1 (fr) Administration transdermique de phycotoxines
CN115916215A (zh) 迷幻剂衍生物的经皮微剂量递送
US4910205A (en) Transdermal delivery of loratadine
JP3483881B2 (ja) 経皮投与用メデトミジン製剤
US7795309B2 (en) Topical formulation including diclofenac, or a pharmaceutically acceptable salt thereof
US4931283A (en) Menthol enhancement of transdermal drug delivery
Roy et al. Transdermal delivery of buprenorphine through cadaver skin
US20010033858A1 (en) Transdermal drug patch
US5464628A (en) Pharmaceutical compositions containing 4-substituted imidazoles to be administered transdermally
US6106856A (en) Transdermal delivery of calcium channel blockers, such as nifedipine
CA2259194C (fr) Compositions transdermiques contenant du levosimendane
US20020127271A1 (en) Formulation for the treatment and/or prophylaxis of dementia
Ita et al. Progress in the transdermal delivery of antimigraine drugs
WO1997006788A1 (fr) Administration trans-cutanee de vorozole
CA2038969A1 (fr) Composes contenant un agent cytotoxique et des stimulateurs de la permeation
EP0918521B1 (fr) Formulation pour le traitement et/ou la prophylaxie de la demence
AU721101C (en) Formulation for the treatment and/or prophylaxis of dementia
EP1216036B1 (fr) Administration transcutanee de n-(2,5-disubstitue phenyl)-n'-(3-substitue phenyl)-n'-methyl guanidines
JP2717859B2 (ja) 経皮吸収製剤
JPH05310569A (ja) カプトプリル含有経皮吸収製剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed